Literature DB >> 24416550

Stereotactic body radiotherapy for superior vena cava syndrome.

Joshua T McKenzie1, Emory McTyre2, Dan Kunaprayoon1, Kevin P Redmond1.   

Abstract

Superior vena cava syndrome (SVCS) is characterized by a spectrum of clinical findings that result from the occlusion of the superior vena cava (SVC), usually caused by extracaval compression of the SVC by either a bronchogenic tumor or an enlarged mediastinal lymph node. Most efforts at treatment for SVCS are palliative, and long-term survival for malignancy-related SVCS is very low. Therefore, radiotherapy treatment is usually delivered with palliative intent utilizing hypofractionated regimens. The use of high dose per fraction may result in more rapid and more durable responses to treatment. Similarly, the high dose per fraction utilized in stereotactic body radiotherapy (SBRT) has been proven highly efficacious in treating early stage non-small cell lung cancer (NSCLC). Here we report the first reported case of a patient with SVCS from NSCLC successfully treated with SBRT to alleviate SVCS.

Entities:  

Keywords:  SBRT; SVCS; Stereotactic; Superior vena cava syndrome

Year:  2013        PMID: 24416550      PMCID: PMC3863254          DOI: 10.1016/j.rpor.2012.12.003

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  9 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Retrospective analysis of the superior vena cava syndrome in irradiated cancer patients.

Authors:  Stephan Mose; Christina Stabik; Klaus Eberlein; Ulla Ramm; Heinz D Böttcher; Kai Budischewski
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

3.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.

Authors:  Robert Timmerman; Ronald McGarry; Constantin Yiannoutsos; Lech Papiez; Kathy Tudor; Jill DeLuca; Marvene Ewing; Ramzi Abdulrahman; Colleen DesRosiers; Mark Williams; James Fletcher
Journal:  J Clin Oncol       Date:  2006-10-20       Impact factor: 44.544

4.  Superior vena caval obstruction. Is it a medical emergency?

Authors:  D E Schraufnagel; R Hill; J A Leech; J A Pare
Journal:  Am J Med       Date:  1981-06       Impact factor: 4.965

5.  A contemporary perspective on superior vena cava syndrome.

Authors:  J C Chen; F Bongard; S R Klein
Journal:  Am J Surg       Date:  1990-08       Impact factor: 2.565

6.  Clinical factors and prognosis in non-small cell lung cancer.

Authors:  S J Martins; J R Pereira
Journal:  Am J Clin Oncol       Date:  1999-10       Impact factor: 2.339

7.  Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  Paul A Kvale; Paul A Selecky; Udaya B S Prakash
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

8.  Role of irradiation in the management of superior vena cava syndrome.

Authors:  B A Armstrong; C A Perez; J R Simpson; M A Hederman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-04       Impact factor: 7.038

Review 9.  Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review.

Authors:  N P Rowell; F V Gleeson
Journal:  Clin Oncol (R Coll Radiol)       Date:  2002-10       Impact factor: 4.126

  9 in total
  2 in total

1.  Stereotactic body radiation therapy for liver metastasis - The linac-based Greater Poland Cancer Centre practice.

Authors:  Magdalena Fundowicz; Marta Adamczyk; Anna Kołodziej-Dybaś
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-04

Review 2.  Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome.

Authors:  Christopher Straka; James Ying; Feng-Ming Kong; Christopher D Willey; Joseph Kaminski; D W Nathan Kim
Journal:  Springerplus       Date:  2016-02-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.